Free Trial

OptimizeRx (OPRX) Financials

OptimizeRx logo
$6.64 -0.70 (-9.50%)
Closing price 03:59 PM Eastern
Extended Trading
$6.74 +0.10 (+1.54%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for OptimizeRx

Annual Income Statements for OptimizeRx

This table shows OptimizeRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-0.60 -1.54 -2.10 0.23 -3.14 -2.28 0.38 -11 -18 -20 5.13
Consolidated Net Income / (Loss)
-0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Net Income / (Loss) Continuing Operations
-0.60 -1.54 -2.10 0.23 -3.14 -2.28 0.38 -11 -18 -20 5.13
Total Pre-Tax Income
-0.60 -1.54 -2.10 0.23 -4.04 -2.21 0.38 -11 -25 -19 6.95
Total Operating Income
-0.60 -1.58 -2.13 0.18 -3.69 -2.14 0.36 -12 -26 -14 12
Total Gross Profit
3.60 4.34 5.95 12 15 24 36 39 43 59 74
Total Revenue
3.60 4.34 5.95 21 25 43 61 62 72 92 109
Operating Revenue
3.60 4.34 5.95 21 25 43 61 62 72 92 109
Total Cost of Revenue
0.00 0.00 0.00 9.00 9.16 19 26 23 29 33 36
Operating Cost of Revenue
- - - 9.00 9.16 19 26 23 29 33 36
Total Operating Expenses
4.20 5.92 8.08 12 19 26 35 51 67 73 62
Selling, General & Admin Expense
3.28 5.08 6.86 9.19 16 21 28 33 44 50 50
Depreciation Expense
0.33 0.24 0.32 0.32 1.28 2.08 2.09 2.02 2.40 4.33 4.33
Other Operating Expenses / (Income)
0.58 0.56 0.90 2.52 2.26 3.17 - - - 11 6.96
Impairment Charge
- - - - - - - 0.00 6.74 7.49 0.37
Total Other Income / (Expense), net
0.00 0.04 0.03 0.05 -0.35 -0.14 0.02 0.85 -0.90 -5.68 -4.74
Interest Expense
0.00 - - - - - - 0.00 1.45 6.16 5.29
Interest & Investment Income
0.00 0.04 0.03 0.05 0.29 0.07 - 0.85 2.19 0.33 0.35
Other Income / (Expense), net
- - - 0.00 -0.64 -0.21 0.02 0.00 -1.64 0.15 0.20
Income Tax Expense
0.00 0.00 0.00 - -0.90 0.00 0.00 0.00 -7.60 0.73 1.82
Basic Earnings per Share
($0.02) ($0.05) ($0.21) - ($0.23) ($0.15) $0.02 ($0.64) ($1.03) ($1.10) $0.28
Weighted Average Basic Shares Outstanding
24.56M 29.71M 9.82M 10.83M 13.39M 14.83M 17.23M 17.78M 17.12M 18.29M 18.56M
Diluted Earnings per Share
($0.02) ($0.05) ($0.21) - ($0.23) ($0.15) $0.02 ($0.64) ($1.03) ($1.10) $0.27
Weighted Average Diluted Shares Outstanding
29.03M 29.71M 9.82M 11.86M 13.39M 14.83M 17.69M 17.78M 17.12M 18.29M 19.00M
Weighted Average Basic & Diluted Shares Outstanding
29.03M 29.71M 29.46M 12.10M 14.64M 16.81M 17.88M 17.10M - - 18.76M

Quarterly Income Statements for OptimizeRx

This table shows OptimizeRx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - 26 24 - - 21 19
Net Income / (Loss) Attributable to Common Shareholders
-6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.69 1.20
Consolidated Net Income / (Loss)
-6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70 1.20
Net Income / (Loss) Continuing Operations
-6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70 1.20
Total Pre-Tax Income
-6.56 -5.10 -9.94 2.21 -3.27 1.73 1.07 7.47 -0.64 -1.10 2.57
Total Operating Income
-5.03 -3.75 -8.56 3.63 -2.10 3.21 2.07 8.57 0.40 -0.09 2.67
Total Gross Profit
12 12 13 22 13 19 18 24 15 16 16
Total Revenue
20 19 21 32 22 29 26 32 20 21 22
Operating Revenue
20 19 21 32 22 29 26 32 20 21 22
Total Cost of Revenue
7.49 7.11 7.86 10 8.58 11 8.55 8.14 4.91 4.82 5.37
Operating Cost of Revenue
7.49 7.11 7.86 10 8.58 11 8.55 8.14 4.91 4.82 5.37
Total Operating Expenses
17 15 22 18 15 15 15 16 15 16 14
Selling, General & Admin Expense
16 14 13 5.83 4.56 3.91 4.17 7.12 3.51 3.70 3.40
Marketing Expense
- - - - 4.99 5.87 5.52 - 4.73 5.53 4.40
Research & Development Expense
- - - - 3.25 3.09 2.72 - 3.40 3.27 2.93
Depreciation Expense
1.07 1.07 1.10 1.09 1.09 1.07 1.08 1.08 1.06 1.06 1.06
Other Operating Expenses / (Income)
- - - - 1.56 1.49 1.96 - 1.83 2.21 1.78
Total Other Income / (Expense), net
-1.53 -1.35 -1.38 -1.43 -1.17 -1.48 -1.00 -1.10 -1.04 -1.01 -0.10
Interest Expense
1.55 1.53 1.52 1.56 1.30 1.60 1.15 1.24 1.16 1.13 0.18
Interest & Investment Income
0.02 0.11 0.11 0.10 0.09 0.09 0.09 0.08 0.08 0.08 0.06
Other Income / (Expense), net
0.00 0.08 0.04 - 0.04 0.04 0.06 0.06 0.04 0.04 0.01
Income Tax Expense
0.34 -1.09 -0.82 2.29 -1.07 0.20 0.29 2.45 -0.15 -0.39 1.37
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)
- - - - - 0.00 0.00 - - -0.01 -0.00
Basic Earnings per Share
($0.38) ($0.22) ($0.50) - ($0.12) $0.08 $0.04 $0.28 ($0.03) ($0.04) $0.06
Weighted Average Basic Shares Outstanding
18.17M 18.26M 18.32M 18.29M 18.47M 18.51M 18.58M 18.56M 18.76M 18.79M 18.87M
Diluted Earnings per Share
($0.38) ($0.22) ($0.50) - ($0.12) $0.08 $0.04 $0.27 ($0.03) ($0.04) $0.06
Weighted Average Diluted Shares Outstanding
18.17M 18.26M 18.32M 18.29M 18.47M 19.02M 19.46M 19.00M 18.76M 18.79M 19.22M
Weighted Average Basic & Diluted Shares Outstanding
18.27M 18.32M - 0.00 18.50M 18.57M 18.64M 18.76M 18.77M 18.84M 18.91M

Annual Cash Flow Statements for OptimizeRx

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
4.76 -1.17 -1.91 3.79 9.94 -8.34 74 -66 -4.36 -0.47 9.99
Net Cash From Operating Activities
0.52 -0.47 -1.48 0.79 -1.66 -6.31 0.73 11 -7.24 4.89 19
Net Cash From Continuing Operating Activities
0.52 -0.47 -1.48 0.79 -1.66 -6.31 0.73 11 -7.24 4.89 19
Net Income / (Loss) Continuing Operations
-0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Consolidated Net Income / (Loss)
-0.60 -1.54 -2.10 0.23 -3.14 -2.21 0.38 -11 -18 -20 5.13
Depreciation Expense
0.33 0.24 0.32 0.32 1.18 1.97 1.97 2.02 2.40 4.33 4.33
Amortization Expense
- - - - - - - 0.00 0.21 0.84 1.11
Non-Cash Adjustments To Reconcile Net Income
1.47 0.83 -0.03 3.25 1.26 3.48 5.57 16 23 19 5.36
Changes in Operating Assets and Liabilities, net
-0.69 0.01 0.33 -3.00 -0.95 -9.55 -7.19 3.96 -16 1.12 2.78
Net Cash From Investing Activities
-0.10 -0.35 -0.04 -5.69 -11 -0.12 -0.49 -58 -25 -0.45 0.07
Net Cash From Continuing Investing Activities
-0.10 -0.35 -0.04 -5.69 -11 -0.12 -0.49 -58 -25 -0.45 0.07
Purchase of Property, Plant & Equipment
-0.00 -0.18 -0.04 -0.03 -0.09 -0.11 -0.46 -0.24 -0.87 -0.45 0.07
Net Cash From Financing Activities
4.35 -0.36 -0.39 8.69 22 -1.90 74 -19 28 -4.91 -8.80
Net Cash From Continuing Financing Activities
4.35 -0.36 -0.39 8.69 22 -1.90 74 -19 28 -4.91 -8.80
Repayment of Debt
- - - - - - - 0.00 -1.71 -4.00 -8.00
Other Financing Activities, net
- - 0.00 0.52 0.88 -1.90 3.25 1.07 -0.28 -0.91 -0.80
Cash Interest Paid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.21 6.20 4.18
Cash Income Taxes Paid
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.16 1.76

Quarterly Cash Flow Statements for OptimizeRx

This table details how cash moves in and out of OptimizeRx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1.33 -0.22 1.17 -2.75 3.19 0.01 2.93 3.85 -3.20 3.93 -1.77
Net Cash From Operating Activities
2.12 0.78 1.79 0.20 3.86 4.56 3.20 7.09 -0.47 8.61 4.74
Net Cash From Continuing Operating Activities
2.12 0.78 1.79 0.20 3.86 4.56 3.20 7.09 -0.47 8.61 4.74
Net Income / (Loss) Continuing Operations
-6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70 1.20
Consolidated Net Income / (Loss)
-6.90 -4.01 -9.12 -0.08 -2.20 1.53 0.78 5.02 -0.50 -0.70 1.20
Depreciation Expense
1.07 1.07 1.10 1.09 1.09 1.07 1.08 1.08 1.06 1.06 1.06
Amortization Expense
0.18 0.18 0.18 0.29 0.17 0.44 0.17 0.33 0.36 0.28 0.04
Non-Cash Adjustments To Reconcile Net Income
0.46 2.18 11 3.01 -1.75 2.34 1.69 3.09 1.83 -0.07 2.57
Changes in Operating Assets and Liabilities, net
7.30 1.35 -1.57 -4.12 6.55 -0.82 -0.53 -2.42 -3.22 8.04 -0.12
Net Cash From Investing Activities
-0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04 -0.01
Net Cash From Continuing Investing Activities
-0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04 -0.01
Purchase of Property, Plant & Equipment
-0.15 -0.09 -0.09 -0.12 -0.08 -0.04 -0.01 0.21 -0.02 -0.04 -0.01
Net Cash From Financing Activities
-0.64 -0.92 -0.53 -2.82 -0.59 -4.51 -0.26 -3.45 -2.71 -4.66 -6.50
Net Cash From Continuing Financing Activities
-0.64 -0.92 -0.53 -2.82 -0.59 -4.51 -0.26 -3.45 -2.71 -4.66 -6.50
Repayment of Debt
-0.50 -0.50 -0.50 -2.50 -0.50 -4.50 -0.50 -2.50 -2.69 -29 -6.31
Other Financing Activities, net
-0.14 -0.42 -0.03 -0.32 -0.09 -0.01 0.24 -0.95 -0.02 -0.05 -0.19
Effect of Exchange Rate Changes
- - - - - - - - - - 0.00
Cash Interest Paid
1.35 1.36 1.37 2.12 1.12 1.17 0.98 0.92 0.80 0.77 0.24
Cash Income Taxes Paid
0.02 0.09 -0.11 0.16 0.00 1.09 -0.08 0.75 0.01 1.21 0.15

Annual Balance Sheets for OptimizeRx

This table presents OptimizeRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
12 11 9.76 25 57 60 141 135 183 171 177
Total Current Assets
11 10 8.81 16 27 33 115 99 54 54 65
Cash & Equivalents
8.21 7.03 5.12 8.91 19 11 85 18 14 13 23
Accounts Receivable
2.85 3.06 3.43 6.46 7.42 18 25 22 36 38 38
Prepaid Expenses
0.07 0.08 0.26 0.36 0.87 4.46 5.63 2.28 3.19 2.38 2.85
Current Deferred & Refundable Income Taxes
- - - - - - - 0.00 1.04 0.00 0.75
Plant, Property, & Equipment, net
0.01 0.17 0.17 0.15 0.18 0.15 0.14 0.14 0.15 0.15 0.11
Total Noncurrent Assets
1.18 1.13 0.79 9.17 29 27 51 36 129 117 112
Goodwill
- - 0.00 3.68 15 15 15 23 78 71 71
Intangible Assets
1.17 1.12 0.78 5.15 5.15 4.52 3.90 3.38 34 37 41
Other Noncurrent Operating Assets
0.01 0.01 0.01 0.34 9.43 8.06 33 9.88 16 8.84 0.43
Total Liabilities & Shareholders' Equity
12 11 9.76 25 57 60 141 135 183 171 177
Total Liabilities
3.37 3.67 3.54 6.60 12 10 9.61 8.54 57 54 49
Total Current Liabilities
3.37 3.67 3.54 4.23 6.11 10 9.37 8.40 18 19 21
Short-Term Debt
- - - - - - - 0.00 2.00 2.00 4.26
Accounts Payable
0.78 0.37 0.46 0.41 0.49 0.62 0.61 1.55 2.23 2.16 1.64
Accrued Expenses
0.01 0.29 0.95 1.30 1.80 2.42 2.90 2.60 7.71 8.49 12
Current Deferred Revenue
0.23 0.39 0.51 0.61 0.58 0.29 1.39 0.16 0.17 0.47 0.50
Other Current Liabilities
2.36 2.62 1.62 1.91 3.23 6.70 4.47 4.08 5.73 5.22 3.28
Total Noncurrent Liabilities
0.00 0.00 0.00 2.37 5.67 0.33 0.24 0.14 39 36 27
Long-Term Debt
- - - - - - - 0.00 34 31 21
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - - - - 0.00 4.34 4.49 5.71
Other Noncurrent Operating Liabilities
- - 0.00 2.37 5.67 0.33 0.24 0.14 0.37 0.21 0.23
Commitments & Contingencies
- - - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
8.94 7.81 6.22 18 45 50 131 126 127 117 128
Total Preferred & Common Equity
8.94 7.81 6.22 18 45 50 131 126 127 117 128
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
8.94 7.81 6.22 18 45 50 131 126 127 117 128
Common Stock
32 34 35 49 78 86 167 173 191 201 208
Retained Earnings
-27 -28 -30 -30 -33 -36 -35 -47 -64 -84 -79
Treasury Stock
- - - - - - 0.00 -0.00 -0.00 - -0.00
Accumulated Other Comprehensive Income / (Loss)
- - - - - - - - - - 0.00

Quarterly Balance Sheets for OptimizeRx

This table presents OptimizeRx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
124 176 173 165 168 169 170 167 164 162
Total Current Assets
87 48 46 47 52 54 56 56 54 53
Cash & Equivalents
9.92 15 15 16 17 17 20 20 24 22
Accounts Receivable
21 30 25 26 33 34 32 32 25 25
Prepaid Expenses
3.01 2.39 4.65 4.39 2.31 3.34 2.83 3.14 2.93 3.88
Current Deferred & Refundable Income Taxes
- 1.04 1.84 0.06 0.11 0.65 1.75 0.87 2.33 1.65
Plant, Property, & Equipment, net
0.15 0.15 0.17 0.16 0.15 0.13 0.12 0.11 0.12 0.12
Total Noncurrent Assets
36 128 127 118 116 115 114 111 110 109
Goodwill
23 78 78 71 71 71 71 71 71 71
Intangible Assets
4.92 48 47 38 37 36 35 33 39 38
Other Noncurrent Operating Assets
8.00 0.53 0.47 9.17 8.46 8.37 7.96 6.95 0.47 0.42
Total Liabilities & Shareholders' Equity
124 176 173 165 168 169 170 167 164 162
Total Liabilities
7.82 54 52 51 51 50 48 38 33 28
Total Current Liabilities
7.70 17 15 15 18 21 18 10 9.71 10
Short-Term Debt
- 3.50 3.30 2.00 3.30 3.30 3.30 2.00 1.25 1.25
Accounts Payable
0.69 1.67 2.98 2.75 3.38 1.98 2.04 3.07 1.32 1.84
Accrued Expenses
3.11 7.28 5.31 5.56 9.28 12 10 3.59 5.39 5.11
Current Deferred Revenue
0.19 0.90 1.05 0.79 0.51 0.48 0.40 0.67 0.71 0.50
Other Current Liabilities
3.71 3.05 2.31 3.41 1.88 2.80 2.54 1.13 1.04 1.78
Total Noncurrent Liabilities
0.12 37 37 36 33 29 30 27 24 18
Long-Term Debt
- 32 32 33 29 25 25 21 18 11
Noncurrent Deferred & Payable Income Tax Liabilities
- 4.34 4.34 2.71 3.79 3.46 4.49 5.66 5.52 6.07
Other Noncurrent Operating Liabilities
0.12 - - 0.24 0.17 0.34 0.30 0.20 0.25 0.19
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
116 123 121 114 116 119 122 130 131 134
Total Preferred & Common Equity
116 123 121 114 116 119 122 130 131 134
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
116 123 121 114 116 119 122 130 131 134
Common Stock
176 194 196 199 203 204 207 209 212 213
Retained Earnings
-60 -71 -75 -84 -87 -85 -84 -80 -80 -79
Treasury Stock
-0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00
Accumulated Other Comprehensive Income / (Loss)
- - - - - - - - 0.01 0.02

Annual Metrics And Ratios for OptimizeRx

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
29,018,425.00 29,672,132.00 29,275,117.00 12,013,682.00 14,173,850.00 15,108,646.00 17,769,544.00 17,152,717.00 18,152,478.00 - 18,640,652.00
DEI Adjusted Shares Outstanding
29,018,425.00 29,672,132.00 29,275,117.00 12,013,682.00 14,173,850.00 15,108,646.00 17,769,544.00 17,152,717.00 18,152,478.00 - 18,640,652.00
DEI Earnings Per Adjusted Shares Outstanding
-0.02 -0.05 -0.07 0.02 -0.22 -0.15 0.02 -0.67 -0.97 - 0.28
Growth Metrics
- - - - - - - - - - -
Revenue Growth
9.66% 20.61% 37.16% 256.24% 15.99% 76.08% 41.51% 1.89% 14.53% 28.81% 18.78%
EBITDA Growth
65.43% -410.99% -34.11% 127.51% -734.96% 88.06% 722.53% -538.20% -147.66% 67.01% 306.53%
EBIT Growth
41.79% -164.73% -34.68% 108.46% -2,503.00% 45.77% 116.11% -3,350.84% -128.17% 51.67% 187.73%
NOPAT Growth
41.79% -164.73% -34.68% 112.08% -1,535.33% 42.19% 124.16% -2,482.59% -114.81% 48.09% 190.00%
Net Income Growth
41.96% -158.63% -36.70% 110.76% -1,488.41% 29.77% 117.13% -3,125.41% -53.57% -14.48% 125.52%
EPS Growth
50.00% -150.00% -320.00% 0.00% 0.00% 34.78% 113.33% -3,300.00% -60.94% -6.80% 124.55%
Operating Cash Flow Growth
1,014.13% -190.46% -217.58% 153.56% -309.55% -279.96% 111.51% 1,367.43% -167.96% 167.53% 282.80%
Free Cash Flow Firm Growth
100.75% -11,602.23% -57.56% -356.35% -130.46% 21.57% -118.23% 136.35% -1,074.00% 102.52% 398.08%
Invested Capital Growth
-36.81% 5.80% 41.21% 769.28% 172.51% 51.70% 83.56% -28.24% 186.57% -8.39% -4.27%
Revenue Q/Q Growth
30.87% 4.90% 50.44% 23.65% 3.36% 26.40% 6.77% -1.04% 13.88% 4.48% -0.07%
EBITDA Q/Q Growth
-170.62% 2.70% 8.09% 45.50% -446.96% 90.14% -24.01% -20.26% -75.66% 63.96% 40.29%
EBIT Q/Q Growth
-1,316.15% 2.95% 5.70% 171.80% -193.35% 59.60% -65.52% -17.18% -71.74% 52.07% 71.44%
NOPAT Q/Q Growth
-951.30% 2.95% 5.70% 171.80% -146.15% 63.25% -67.07% -13.75% -61.68% 51.53% 6,422.76%
Net Income Q/Q Growth
-1,280.97% 3.86% 5.21% 128.17% -147.89% 60.23% -65.99% -9.05% -27.75% 16.81% 15,451.52%
EPS Q/Q Growth
-300.00% -25.00% -31.25% 0.00% 0.00% 61.54% -71.43% -12.28% -27.16% 18.52% 0.00%
Operating Cash Flow Q/Q Growth
-32.29% -1,887.14% 22.13% 687.10% -315.16% -20.94% 236.47% 63.51% -497.48% 412.17% 58.27%
Free Cash Flow Firm Q/Q Growth
-98.27% -112.30% 15.90% -220.93% -104.05% 44.13% -441.84% 171.50% -829.43% 102.86% 397.98%
Invested Capital Q/Q Growth
-31.01% 66.80% 5.66% 159.28% 117.34% 13.88% 73.43% 2.36% 187.71% 2.11% -0.18%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 57.56% 62.77% 55.65% 58.14% 62.40% 59.98% 64.45% 67.25%
EBITDA Margin
-7.32% -31.02% -30.33% 2.34% -12.82% -0.87% 3.82% -16.44% -35.56% -9.11% 15.83%
Operating Margin
-16.60% -36.44% -35.78% 0.85% -15.02% -4.93% 0.59% -19.68% -36.91% -14.88% 10.69%
EBIT Margin
-16.60% -36.44% -35.78% 0.85% -17.60% -5.42% 0.62% -19.68% -39.21% -14.71% 10.87%
Profit (Net Income) Margin
-16.54% -35.47% -35.35% 1.07% -12.78% -5.10% 0.62% -18.32% -24.56% -21.83% 4.69%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 77.78% 100.00% 100.00% 100.00% 69.81% 103.74% 73.84%
Interest Burden Percent
99.62% 97.32% 98.78% 125.65% 93.35% 94.02% 100.00% 93.07% 89.73% 143.02% 58.45%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.16%
Return on Invested Capital (ROIC)
-44.06% -146.39% -159.00% 3.39% -14.54% -4.57% 0.65% -13.83% -18.40% -6.72% 6.47%
ROIC Less NNEP Spread (ROIC-NNEP)
-41.03% -140.72% -148.91% 2.73% -10.53% 0.29% 0.60% -9.57% -21.94% -57.02% -25.74%
Return on Net Nonoperating Assets (RNNOA)
35.28% 128.02% 129.01% -1.55% 4.62% -0.09% -0.23% 4.95% 4.49% -9.79% -2.28%
Return on Equity (ROE)
-8.78% -18.37% -29.99% 1.83% -9.93% -4.65% 0.42% -8.88% -13.90% -16.51% 4.18%
Cash Return on Invested Capital (CROIC)
1.05% -152.02% -193.17% -155.35% -107.16% -45.65% -58.29% 19.06% -114.92% 2.04% 10.83%
Operating Return on Assets (OROA)
-6.18% -13.29% -20.05% 1.03% -10.60% -4.01% 0.38% -8.92% -17.64% -7.65% 6.83%
Return on Assets (ROA)
-6.15% -12.94% -19.81% 1.30% -7.69% -3.77% 0.38% -8.30% -11.05% -11.34% 2.95%
Return on Common Equity (ROCE)
-8.78% -18.37% -29.99% 1.83% -9.93% -4.65% 0.42% -8.88% -13.90% -16.51% 4.18%
Return on Equity Simple (ROE_SIMPLE)
-6.66% -19.70% -33.82% 1.23% -7.00% -4.42% 0.29% -9.07% -13.88% -17.19% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.42 -1.11 -1.49 0.18 -2.59 -1.49 0.36 -8.60 -18 -9.59 8.63
NOPAT Margin
-11.62% -25.51% -25.05% 0.85% -10.51% -3.45% 0.59% -13.78% -25.84% -10.41% 7.89%
Net Nonoperating Expense Percent (NNEP)
-3.04% -5.67% -10.09% 0.66% -4.01% -4.85% 0.05% -4.26% 3.54% 50.30% 32.21%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -11.35% -6.40% 5.61%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 42.44% 37.23% 44.35% 41.86% 37.60% 40.02% 35.55% 32.75%
SG&A Expenses to Revenue
91.17% 116.98% 115.17% 43.33% 63.38% 48.47% 45.19% 53.63% 61.94% 54.05% 45.92%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
116.60% 136.44% 135.78% 56.71% 77.78% 60.58% 57.56% 82.08% 93.90% 79.33% 56.57%
Earnings before Interest and Taxes (EBIT)
-0.60 -1.58 -2.13 0.18 -4.33 -2.35 0.38 -12 -28 -14 12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-0.26 -1.35 -1.81 0.50 -3.15 -0.38 2.34 -10 -25 -8.39 17
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.22 4.94 2.05 7.05 3.06 9.25 8.36 2.37 1.94 0.76 1.82
Price to Tangible Book Value (P/TBV)
4.86 5.77 2.35 13.52 5.51 15.04 9.75 2.99 17.51 6.21 8.29
Price to Revenue (P/Rev)
10.49 8.90 2.14 6.14 5.59 10.67 17.93 4.78 3.43 0.97 2.13
Price to Earnings (P/E)
0.00 0.00 0.00 574.95 0.00 0.00 2,906.16 0.00 0.00 0.00 45.39
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.17% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 2.20%
Enterprise Value to Invested Capital (EV/IC)
40.18 40.62 6.96 12.70 4.56 11.44 14.00 4.32 1.80 0.79 1.80
Enterprise Value to Revenue (EV/Rev)
8.21 7.28 1.28 5.72 4.82 10.42 16.54 3.60 3.74 1.18 2.15
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 244.09 0.00 0.00 432.74 0.00 0.00 0.00 13.58
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 672.97 0.00 0.00 2,682.18 0.00 0.00 0.00 19.78
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 672.97 0.00 0.00 2,808.29 0.00 0.00 0.00 27.24
Enterprise Value to Operating Cash Flow (EV/OCF)
57.33 0.00 0.00 152.95 0.00 0.00 1,396.72 21.08 0.00 22.16 12.57
Enterprise Value to Free Cash Flow (EV/FCFF)
2,954.71 0.00 0.00 0.00 0.00 0.00 0.00 18.95 0.00 37.31 16.26
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.29 0.28 0.20
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.27 0.26 0.17
Financial Leverage
-0.86 -0.91 -0.87 -0.57 -0.44 -0.31 -0.38 -0.52 -0.20 0.17 0.09
Leverage Ratio
1.43 1.42 1.51 1.41 1.29 1.23 1.11 1.07 1.26 1.46 1.42
Compound Leverage Factor
1.42 1.38 1.50 1.77 1.20 1.16 1.11 1.00 1.13 2.08 0.83
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.26% 21.90% 16.68%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.23% 1.34% 2.76%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.03% 20.57% 13.91%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 77.74% 78.10% 83.32%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.42 -3.91 1.48
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.88 -2.32 0.13
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.35 -3.67 1.24
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.96 -3.42 2.97
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.21 -2.03 0.27
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.85 -3.21 2.48
Altman Z-Score
4.57 3.48 -1.66 11.57 6.81 26.99 69.63 21.47 2.22 0.82 3.38
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.30 2.78 2.49 3.72 4.44 3.28 12.29 11.74 3.04 2.89 3.04
Quick Ratio
3.28 2.75 2.41 3.63 4.30 2.83 11.69 11.47 2.80 2.77 2.87
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.01 -1.15 -1.81 -8.27 -19 -15 -33 12 -115 2.90 14
Operating Cash Flow to CapEx
25,176.44% -261.14% -3,503.14% 2,306.49% -1,893.36% -5,594.66% 156.31% 4,356.34% -840.88% 1,086.44% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -79.40 0.47 2.73
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -4.98 0.79 3.54
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.57 0.72 3.55
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.37 0.36 0.56 1.22 0.60 0.74 0.61 0.45 0.45 0.52 0.63
Accounts Receivable Turnover
1.45 1.47 1.83 4.29 3.55 3.42 2.87 2.66 2.45 2.47 2.88
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
312.21 47.20 34.92 133.95 151.21 266.65 418.85 444.06 499.37 616.23 854.91
Accounts Payable Turnover
0.00 0.00 0.00 20.73 20.26 34.57 41.88 21.78 15.16 14.94 18.90
Days Sales Outstanding (DSO)
250.93 248.43 199.01 85.10 102.95 106.62 127.10 137.22 149.04 147.51 126.69
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 17.61 18.01 10.56 8.71 16.76 24.08 24.43 19.31
Cash Conversion Cycle (CCC)
250.93 248.43 199.01 67.49 84.93 96.06 118.38 120.46 124.96 123.09 107.38
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.73 0.78 1.10 9.54 26 39 72 52 149 136 131
Invested Capital Turnover
3.79 5.74 6.35 3.99 1.38 1.32 1.10 1.00 0.71 0.65 0.82
Increase / (Decrease) in Invested Capital
-0.43 0.04 0.32 8.45 16 13 33 -20 97 -12 -5.83
Enterprise Value (EV)
30 32 7.64 121 119 452 1,014 225 267 108 235
Market Capitalization
38 39 13 130 137 462 1,099 299 245 89 233
Book Value per Share
$0.31 $0.26 $0.21 $1.54 $3.17 $3.31 $7.39 $7.35 $6.97 $6.40 $6.88
Tangible Book Value per Share
$0.27 $0.23 $0.19 $0.80 $1.76 $2.03 $6.34 $5.83 $0.77 $0.78 $1.51
Total Capital
8.94 7.81 6.22 18 45 50 131 126 163 150 154
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 36 33 26
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 34 31 21
Net Debt
-8.21 -7.03 -5.12 -8.91 -19 -11 -85 -74 22 19 2.31
Capital Expenditures (CapEx)
0.00 0.18 0.04 0.03 0.09 0.11 0.46 0.24 0.86 0.45 -0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-0.45 -0.53 0.14 2.59 2.18 12 21 16 25 24 24
Debt-free Net Working Capital (DFNWC)
7.75 6.51 5.27 12 21 23 106 90 38 37 48
Net Working Capital (NWC)
7.75 6.51 5.27 12 21 23 106 90 36 35 43
Net Nonoperating Expense (NNE)
0.18 0.43 0.61 -0.05 0.56 0.71 -0.02 2.83 -0.92 11 3.50
Net Nonoperating Obligations (NNO)
-8.21 -7.03 -5.12 -8.91 -19 -11 -59 -74 22 19 2.31
Total Depreciation and Amortization (D&A)
0.33 0.24 0.32 0.32 1.18 1.97 1.97 2.02 2.61 5.16 5.44
Debt-free, Cash-free Net Working Capital to Revenue
-12.61% -12.11% 2.40% 12.20% 8.87% 28.43% 34.36% 25.68% 34.39% 25.98% 22.24%
Debt-free Net Working Capital to Revenue
215.48% 149.98% 88.46% 54.23% 85.51% 52.71% 172.52% 144.40% 53.76% 40.51% 43.60%
Net Working Capital to Revenue
215.48% 149.98% 88.46% 54.23% 85.51% 52.71% 172.52% 144.40% 50.96% 38.34% 39.71%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.02) ($0.05) ($0.07) $0.02 $0.00 ($0.15) $0.00 ($0.64) ($1.03) ($1.10) $0.28
Adjusted Weighted Average Basic Shares Outstanding
24.56M 29.71M 29.32M 10.83M 13.39M 14.83M 0.00 17.78M 17.12M 18.29M 18.56M
Adjusted Diluted Earnings per Share
($0.02) ($0.05) ($0.07) $0.02 $0.00 ($0.15) $0.00 ($0.64) ($1.03) ($1.10) $0.27
Adjusted Weighted Average Diluted Shares Outstanding
29.03M 29.72M 29.32M 11.86M 13.39M 14.83M 0.00 17.78M 17.12M 18.29M 19.00M
Adjusted Basic & Diluted Earnings per Share
($0.02) ($0.05) ($0.07) $0.02 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
29.03M 29.72M 29.46M 12.10M 14.64M 16.81M 0.00 17.10M 0.00 0.00 18.76M
Normalized Net Operating Profit after Tax (NOPAT)
-0.42 -1.07 -1.49 0.13 -2.59 -1.49 4.10 2.42 -4.16 3.68 8.91
Normalized NOPAT Margin
-11.62% -24.70% -25.05% 0.59% -10.51% -3.45% 6.68% 3.87% -5.82% 3.99% 8.14%
Pre Tax Income Margin
-16.54% -35.47% -35.35% 1.07% -16.43% -5.10% 0.62% -18.32% -35.18% -21.04% 6.35%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.29 -2.20 2.25
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.71 -1.56 1.63
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -19.88 -2.27 2.26
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -13.30 -1.63 1.64
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% -52.42% -18.54% 0.00% 0.00% 0.00% 0.00% -175.06% -42.82% 0.00% 0.00%

Quarterly Metrics And Ratios for OptimizeRx

This table displays calculated financial ratios and metrics derived from OptimizeRx's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
18,152,478.00 18,152,478.00 18,152,478.00 - 18,152,478.00 18,495,111.00 18,565,033.00 18,640,652.00 18,762,203.00 18,765,075.00 18,835,951.00
DEI Adjusted Shares Outstanding
18,152,478.00 18,152,478.00 18,152,478.00 - 18,152,478.00 18,495,111.00 18,565,033.00 18,640,652.00 18,762,203.00 18,765,075.00 18,835,951.00
DEI Earnings Per Adjusted Shares Outstanding
-0.38 -0.22 -0.50 - -0.12 0.08 0.04 0.27 -0.03 -0.04 0.06
Growth Metrics
- - - - - - - - - - -
Revenue Growth
51.43% 36.14% 30.48% 13.91% 11.37% 55.19% 22.33% -0.24% -9.50% -29.77% -17.08%
EBITDA Growth
42.72% 44.84% -134.76% 151.61% 78.97% 295.91% 146.46% 98.44% 333.46% -72.85% 11.57%
EBIT Growth
28.80% 24.23% -139.91% 133.23% 58.98% 187.81% 124.78% 134.90% 121.04% -101.54% 25.69%
NOPAT Growth
28.80% 22.69% -140.98% 98.30% 58.20% 208.68% 125.40% 4,525.24% 118.84% -102.17% -17.53%
Net Income Growth
-7.83% 3.68% -218.46% 98.09% 68.13% 138.22% 108.54% 6,454.43% 77.49% -145.89% 53.40%
EPS Growth
-2.70% 8.33% -194.12% 0.00% 68.42% 136.36% 108.00% 0.00% 75.00% -150.00% 50.00%
Operating Cash Flow Growth
2,562.79% 133.01% 21.59% 103.16% 82.44% 483.25% 78.78% 3,479.80% -112.09% 88.80% 47.91%
Free Cash Flow Firm Growth
-634.93% -2,889.73% -2,426.18% 111.82% 109.79% 114.52% 104.89% -6.33% -103.40% -61.59% 82.40%
Invested Capital Growth
184.68% 166.59% 158.12% -8.39% -7.62% -7.32% -2.07% -4.27% 0.45% -3.91% -5.02%
Revenue Q/Q Growth
-30.60% -4.46% 13.27% 51.65% -32.15% 33.14% -10.71% 23.68% -38.45% 3.33% 5.42%
EBITDA Q/Q Growth
61.11% 36.03% -199.71% 169.21% -115.73% 686.99% -28.92% 197.92% -81.50% -30.44% 192.80%
EBIT Q/Q Growth
54.02% 26.94% -132.01% 142.63% -156.17% 255.47% -34.53% 308.52% -94.97% -111.52% 5,462.00%
NOPAT Q/Q Growth
54.02% 25.45% -128.38% 97.83% -1,031.15% 292.73% -46.62% 278.12% -95.18% -122.22% 2,118.56%
Net Income Q/Q Growth
-66.56% 41.90% -127.64% 99.13% -2,683.54% 169.67% -49.15% 544.42% -109.86% -42.02% 269.99%
EPS Q/Q Growth
-52.00% 42.11% -127.27% 0.00% 0.00% 166.67% -50.00% 575.00% -111.11% -33.33% 250.00%
Operating Cash Flow Q/Q Growth
133.84% -63.08% 129.03% -88.94% 1,851.52% 18.04% -29.80% 121.36% -106.59% 1,943.90% -45.00%
Free Cash Flow Firm Q/Q Growth
7.91% 5.51% 3.51% 114.08% -23.77% 40.29% -67.51% 169.78% -102.77% 1,680.86% 53.93%
Invested Capital Q/Q Growth
-3.92% -1.12% -5.56% 2.11% -3.11% -0.80% -0.21% -0.18% 1.67% -5.12% -1.36%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
61.98% 62.22% 63.10% 68.15% 60.85% 63.83% 67.20% 74.75% 75.25% 76.51% 75.16%
EBITDA Margin
-19.20% -12.85% -34.01% 15.52% -3.63% 16.23% 12.92% 31.11% 9.35% 6.30% 17.49%
Operating Margin
-25.54% -19.93% -40.18% 11.25% -9.59% 10.92% 7.86% 26.58% 2.00% -0.43% 12.35%
EBIT Margin
-25.54% -19.53% -40.00% 11.25% -9.41% 11.05% 8.10% 26.76% 2.19% -0.24% 12.40%
Profit (Net Income) Margin
-35.04% -21.31% -42.82% -0.24% -10.03% 5.25% 2.99% 15.57% -2.49% -3.43% 5.53%
Tax Burden Percent
105.25% 78.65% 91.78% -3.58% 67.21% 89.43% 74.26% 67.18% 76.86% 64.14% 46.57%
Interest Burden Percent
130.34% 138.70% 116.62% 60.73% 158.60% 53.10% 49.67% 86.60% -148.39% 2,192.00% 95.71%
Effective Tax Rate
0.00% 0.00% 0.00% 103.58% 0.00% 10.57% 25.74% 32.82% 0.00% 0.00% 53.43%
Return on Invested Capital (ROIC)
-14.46% -11.93% -26.76% -0.26% -4.60% 7.51% 4.84% 14.63% 1.13% -0.23% 4.25%
ROIC Less NNEP Spread (ROIC-NNEP)
-1.75% -5.38% -12.90% -0.02% -8.59% -0.66% -0.52% 7.86% -6.96% -19.23% 13.80%
Return on Net Nonoperating Assets (RNNOA)
0.38% 0.96% 2.53% 0.00% -1.31% -0.09% -0.06% 0.70% -0.54% -0.52% -0.05%
Return on Equity (ROE)
-14.09% -10.97% -24.23% -0.26% -5.91% 7.42% 4.78% 15.33% 0.59% -0.75% 4.19%
Cash Return on Invested Capital (CROIC)
-113.66% -107.63% -109.66% 2.04% 2.44% 5.62% 2.20% 10.83% 7.19% 9.77% 10.63%
Operating Return on Assets (OROA)
-12.97% -11.05% -24.40% 5.84% -5.16% 6.77% 5.29% 16.83% 1.40% -0.14% 7.03%
Return on Assets (ROA)
-17.79% -12.05% -26.12% -0.13% -5.50% 3.21% 1.95% 9.79% -1.60% -2.03% 3.13%
Return on Common Equity (ROCE)
-14.09% -10.97% -24.23% -0.26% -5.91% 7.42% 4.78% 15.33% 0.59% -0.75% 4.19%
Return on Equity Simple (ROE_SIMPLE)
-14.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-3.52 -2.62 -5.99 -0.13 -1.47 2.85 1.52 5.76 0.28 -0.06 1.24
NOPAT Margin
-17.88% -13.95% -28.13% -0.40% -6.71% 9.77% 5.84% 17.86% 1.40% -0.30% 5.75%
Net Nonoperating Expense Percent (NNEP)
-12.71% -6.55% -13.86% -0.24% 3.99% 8.17% 5.36% 6.77% 8.09% 19.00% -9.55%
Return On Investment Capital (ROIC_SIMPLE)
-2.22% -1.67% -4.00% -0.09% -0.99% 1.93% 1.01% 3.74% 0.18% -0.04% 0.85%
Cost of Revenue to Revenue
38.02% 37.78% 36.90% 31.85% 39.15% 36.17% 32.80% 25.25% 24.75% 23.49% 24.84%
SG&A Expenses to Revenue
82.10% 76.44% 63.00% 18.03% 20.78% 49.23% 55.19% 22.09% 17.70% 18.06% 15.73%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 14.83% 0.00% 0.00% 0.00% 17.14% 15.97% 13.55%
Operating Expenses to Revenue
87.52% 82.14% 103.29% 56.90% 70.44% 52.91% 59.33% 48.18% 73.25% 76.94% 62.81%
Earnings before Interest and Taxes (EBIT)
-5.03 -3.67 -8.52 3.63 -2.06 3.23 2.11 8.63 0.43 -0.05 2.68
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.78 -2.42 -7.25 5.02 -0.80 4.74 3.37 10 1.86 1.29 3.78
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.80 1.51 1.24 0.76 1.38 2.15 3.26 1.82 0.91 0.82 1.20
Price to Tangible Book Value (P/TBV)
0.00 0.00 25.72 6.21 18.12 20.37 24.42 8.29 4.61 5.00 6.33
Price to Revenue (P/Rev)
2.82 2.19 1.60 0.97 1.70 2.45 3.64 2.13 1.10 1.09 1.70
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 12,088.71 45.39 17.24 23.30 31.90
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 2.20% 5.80% 4.29% 3.14%
Enterprise Value to Invested Capital (EV/IC)
1.69 1.44 1.20 0.79 1.33 2.05 3.11 1.80 0.91 0.81 1.21
Enterprise Value to Revenue (EV/Rev)
3.09 2.44 1.82 1.18 1.86 2.56 3.72 2.15 1.13 1.04 1.60
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 154.52 32.99 13.58 6.06 6.20 8.93
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 58.75 19.78 8.41 9.23 12.96
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 3,078.51 27.24 11.95 13.78 21.58
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 22.16 26.51 25.79 34.46 12.57 8.41 5.55 7.56
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 37.31 52.43 35.03 140.31 16.26 12.70 8.15 11.13
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.30 0.30 0.31 0.28 0.28 0.24 0.23 0.20 0.18 0.15 0.10
Long-Term Debt to Equity
0.27 0.27 0.29 0.26 0.25 0.21 0.20 0.17 0.16 0.14 0.09
Financial Leverage
-0.22 -0.18 -0.20 0.17 0.15 0.13 0.12 0.09 0.08 0.03 0.00
Leverage Ratio
1.25 1.24 1.25 1.46 1.44 1.42 1.42 1.42 1.36 1.33 1.30
Compound Leverage Factor
1.63 1.72 1.46 0.88 2.29 0.76 0.70 1.23 -2.02 29.21 1.24
Debt to Total Capital
22.82% 22.86% 23.56% 21.90% 21.84% 19.25% 18.69% 16.68% 15.26% 12.66% 8.68%
Short-Term Debt to Total Capital
2.20% 2.10% 1.34% 1.34% 2.22% 2.23% 2.19% 2.76% 1.31% 0.83% 0.85%
Long-Term Debt to Total Capital
20.61% 20.76% 22.22% 20.57% 19.62% 17.01% 16.49% 13.91% 13.95% 11.83% 7.83%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
77.18% 77.14% 76.44% 78.10% 78.16% 80.76% 81.31% 83.32% 84.74% 87.34% 91.32%
Debt to EBITDA
-1.73 -1.88 -1.52 -3.91 -6.01 16.36 2.28 1.48 1.17 1.15 0.75
Net Debt to EBITDA
-0.98 -1.07 -0.82 -2.32 -2.94 6.81 0.69 0.13 0.16 -0.31 -0.57
Long-Term Debt to EBITDA
-1.56 -1.71 -1.43 -3.67 -5.40 14.46 2.01 1.24 1.07 1.08 0.68
Debt to NOPAT
-2.12 -2.20 -1.78 -3.42 -4.31 -10.54 212.29 2.97 2.30 2.56 1.82
Net Debt to NOPAT
-1.20 -1.26 -0.97 -2.03 -2.11 -4.39 64.83 0.27 0.31 -0.69 -1.37
Long-Term Debt to NOPAT
-1.92 -2.00 -1.68 -3.21 -3.87 -9.32 187.36 2.48 2.11 2.39 1.64
Altman Z-Score
2.46 2.13 1.56 1.15 1.90 3.29 5.24 3.32 2.19 2.18 3.68
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.88 3.07 3.23 2.89 2.82 2.57 3.05 3.04 5.37 5.58 5.06
Quick Ratio
2.68 2.64 2.93 2.77 2.69 2.38 2.80 2.87 4.99 5.03 4.53
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-96 -91 -88 12 9.43 13 4.29 12 -0.32 5.07 7.81
Operating Cash Flow to CapEx
1,384.31% 920.00% 1,946.74% 165.00% 4,600.00% 10,365.91% 32,020.00% 0.00% -2,223.81% 24,602.86% 39,466.67%
Free Cash Flow to Firm to Interest Expense
-62.32 -59.58 -57.64 7.92 7.27 8.24 3.72 9.34 -0.28 4.50 44.10
Operating Cash Flow to Interest Expense
1.37 0.51 1.18 0.13 2.98 2.85 2.77 5.72 -0.40 7.64 26.76
Operating Cash Flow Less CapEx to Interest Expense
1.27 0.46 1.11 0.05 2.91 2.82 2.77 5.88 -0.42 7.61 26.69
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.51 0.57 0.61 0.52 0.55 0.61 0.65 0.63 0.64 0.59 0.57
Accounts Receivable Turnover
3.26 3.89 3.74 2.47 3.02 3.61 3.74 2.88 3.32 3.38 3.28
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
526.79 533.41 568.35 616.23 622.87 686.87 782.19 854.91 835.37 770.73 805.15
Accounts Payable Turnover
20.68 16.67 19.15 14.94 13.42 15.03 15.86 18.90 9.98 15.99 11.99
Days Sales Outstanding (DSO)
111.80 93.88 97.61 147.51 120.81 101.11 97.58 126.69 110.01 107.86 111.21
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
17.65 21.90 19.06 24.43 27.21 24.28 23.02 19.31 36.58 22.83 30.44
Cash Conversion Cycle (CCC)
94.15 71.99 78.55 123.09 93.60 76.83 74.57 107.38 73.43 85.03 80.77
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
143 141 134 136 132 131 131 131 133 126 124
Invested Capital Turnover
0.81 0.86 0.95 0.65 0.69 0.77 0.83 0.82 0.81 0.77 0.74
Increase / (Decrease) in Invested Capital
93 88 82 -12 -11 -10 -2.77 -5.83 0.60 -5.13 -6.56
Enterprise Value (EV)
241 203 161 108 176 269 408 235 121 102 151
Market Capitalization
221 183 141 89 160 257 399 233 118 107 161
Book Value per Share
$6.75 $6.63 $6.25 $6.40 $6.29 $6.45 $6.59 $6.88 $6.91 $6.99 $7.11
Tangible Book Value per Share
($0.24) ($0.26) $0.30 $0.78 $0.48 $0.68 $0.88 $1.51 $1.36 $1.15 $1.35
Total Capital
159 157 150 150 149 148 150 154 153 150 147
Total Debt
36 36 35 33 32 28 28 26 23 19 13
Total Long-Term Debt
33 33 33 31 29 25 25 21 21 18 11
Net Debt
21 20 19 19 16 12 8.58 2.31 3.17 -5.09 -9.60
Capital Expenditures (CapEx)
0.15 0.09 0.09 0.12 0.08 0.04 0.01 -0.21 0.02 0.04 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)
20 19 18 24 20 20 22 24 28 22 21
Debt-free Net Working Capital (DFNWC)
35 34 34 37 37 36 41 48 48 46 44
Net Working Capital (NWC)
32 31 32 35 33 33 38 43 46 44 43
Net Nonoperating Expense (NNE)
3.38 1.38 3.13 -0.05 0.73 1.32 0.74 0.74 0.77 0.64 0.05
Net Nonoperating Obligations (NNO)
21 20 19 19 16 12 8.58 2.31 3.17 -5.09 -9.60
Total Depreciation and Amortization (D&A)
1.25 1.26 1.28 1.38 1.27 1.51 1.26 1.40 1.42 1.34 1.10
Debt-free, Cash-free Net Working Capital to Revenue
25.46% 23.26% 20.73% 25.98% 21.29% 18.84% 19.76% 22.24% 25.65% 21.88% 22.79%
Debt-free Net Working Capital to Revenue
44.86% 41.24% 39.02% 40.51% 38.85% 34.68% 37.58% 43.60% 44.44% 46.31% 46.49%
Net Working Capital to Revenue
40.39% 37.27% 36.75% 38.34% 35.35% 31.53% 34.57% 39.71% 42.58% 45.04% 45.17%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.38) ($0.22) ($0.50) $0.00 ($0.12) $0.08 $0.04 $0.28 ($0.03) ($0.04) $0.06
Adjusted Weighted Average Basic Shares Outstanding
18.17M 18.26M 18.32M 18.29M 18.47M 18.51M 18.58M 18.56M 18.76M 18.79M 18.87M
Adjusted Diluted Earnings per Share
($0.38) ($0.22) ($0.50) $0.00 ($0.12) $0.08 $0.04 $0.27 ($0.03) ($0.04) $0.06
Adjusted Weighted Average Diluted Shares Outstanding
18.17M 18.26M 18.32M 18.29M 18.47M 19.02M 19.46M 19.00M 18.76M 18.79M 19.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
18.27M 18.32M 0.00 0.00 18.50M 18.57M 18.64M 18.76M 18.77M 18.84M 18.91M
Normalized Net Operating Profit after Tax (NOPAT)
-3.52 -2.62 -0.75 2.54 -1.47 2.85 1.52 5.76 0.28 -0.06 1.87
Normalized NOPAT Margin
-17.88% -13.95% -3.52% 7.87% -6.71% 9.77% 5.84% 17.86% 1.40% -0.30% 8.65%
Pre Tax Income Margin
-33.29% -27.09% -46.65% 6.83% -14.92% 5.87% 4.02% 23.18% -3.25% -5.35% 11.87%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-3.25 -2.40 -5.59 2.33 -1.59 2.01 1.83 6.96 0.38 -0.04 15.15
NOPAT to Interest Expense
-2.28 -1.72 -3.93 -0.08 -1.13 1.78 1.32 4.64 0.24 -0.05 7.03
EBIT Less CapEx to Interest Expense
-3.35 -2.46 -5.65 2.25 -1.66 1.99 1.82 7.12 0.36 -0.08 15.08
NOPAT Less CapEx to Interest Expense
-2.38 -1.77 -3.99 -0.16 -1.20 1.75 1.31 4.81 0.22 -0.09 6.96
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

OptimizeRx’s Q2 2026 statements show improving liquidity and cash generation, but weakening revenue and profitability remain important concerns. Revenue was $20.5 million, down 29.8% from $29.2 million in Q2 2025, although it increased 3.3% sequentially from Q1 2026. The company’s recent revenue level also remains below Q3 and Q4 2025, when revenue was $26.1 million and $32.2 million, respectively.

Profitability deteriorated year over year. Gross margin improved substantially to approximately 76.5% from 63.8% in Q2 2025, but that benefit was offset by lower revenue and operating expenses that remained relatively high. OptimizeRx recorded an operating loss of $88,000 and a net loss of $703,000, compared with operating income of $3.2 million and net income of $1.5 million in the prior-year quarter.

  • Cash flow improved sharply in Q2 2026. Operating cash flow was $8.6 million, compared with $4.6 million in Q2 2025 and negative $467,000 in Q1 2026. However, much of the quarterly improvement came from an $8.0 million favorable change in operating assets and liabilities, which may not be fully recurring.
  • Liquidity strengthened. Cash and equivalents rose to $24.1 million from $16.6 million in Q2 2025 and $20.2 million in Q1 2026. Current assets of $54.1 million compared with current liabilities of $9.7 million, indicating a strong current liquidity position.
  • Accounts receivable declined to $24.8 million from $33.5 million a year earlier. Combined with stronger operating cash flow, this suggests improved collections and a reduced amount of cash tied up in receivables.
  • Debt and interest costs have declined. Total short- and long-term debt was approximately $19.0 million at the end of Q2 2026, down from $28.4 million in Q2 2025. Quarterly interest expense also fell to $1.1 million from $1.6 million.
  • Gross-margin performance improved materially. Cost of revenue fell to 23.5% of revenue in Q2 2026 from 36.2% in the prior-year quarter, indicating a more favorable revenue mix or improved delivery economics.
  • Capital spending remains modest. OptimizeRx spent only $35,000 on property and equipment in Q2 2026, compared with $44,000 in Q2 2025. This supports near-term free cash flow, although limited investment could constrain future expansion if growth opportunities require additional infrastructure.
  • The balance sheet is increasingly concentrated in goodwill and intangible assets. These assets totaled approximately $109.6 million, or roughly two-thirds of total assets, at June 30, 2026. Their value depends on the continued performance of acquired businesses and could be vulnerable to future impairment charges.
  • Revenue momentum has weakened. Q2 2026 revenue was down nearly 30% year over year and remained well below Q4 2025. Sustained revenue pressure could make it difficult for the company to support its current spending structure.
  • Profitability has regressed after a profitable Q4 2025. OptimizeRx reported net losses in both Q1 and Q2 2026, following $5.0 million of net income in Q4 2025 and $779,000 in Q3 2025. The company must return to consistent operating profitability for earnings quality to improve.
  • Operating expenses remain heavy relative to revenue. Selling, general and administrative, marketing, research and development, depreciation, and other operating expenses totaled $15.8 million in Q2 2026—nearly equal to gross profit of $15.7 million. This left little room for interest expense and other costs.

Overall, OptimizeRx has a healthier liquidity profile, lower debt burden, and stronger recent operating cash flow. The central risk is that Q2’s cash generation was helped by working-capital movements while the income statement continued to show losses. Investors will likely want to see a sustained recovery in revenue and operating profitability before treating the balance-sheet improvements as evidence of a durable turnaround.

11/16/26 04:11 PM ETAI Generated. May Contain Errors.

OptimizeRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OptimizeRx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

OptimizeRx's net income appears to be on a downward trend, with a most recent value of $5.13 million in 2025, compared with -$595.14 thousand in 2015. The previous period was -$20.11 million in 2024. See where experts think OptimizeRx is headed by visiting OptimizeRx's forecast page.

OptimizeRx's total operating income in 2025 was $11.69 million, based on the following breakdown:
  • Total Gross Profit: $73.60 million
  • Total Operating Expenses: $61.90 million

Over the last 10 years, OptimizeRx's total revenue changed from $3.60 million in 2015 to $109.43 million in 2025, a change of 2,941.0%.

In the past 12 quarters, OptimizeRx's cash and equivalents has ranged from $9.92 million in Q3 2023 to $24.10 million in Q2 2026, and is currently $22.33 million as of their latest financial filing in Q3 2026.

OptimizeRx had total debt of $25.68 million at the end of 2025, a 21.8% decrease from 2024, and none in 2015.

Over the last 10 years, OptimizeRx's book value per share changed from 0.31 in 2015 to 6.88 in 2025, a change of 2,133.1%.



Financial statements for NASDAQ:OPRX last updated on 11/13/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners